This biotech’s stock rockets on oral obesity-drug partnership with Wegovy parent MarketWatch 2025-05-14 16:46 Source Original site Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments.